A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer.
Not Applicable
- Conditions
- advanced gastric cancer
- Registration Number
- JPRN-UMIN000006403
- Lead Sponsor
- Toyama Prefectural Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
central nervous system metastasis other active double cancer inadequately controlled diabetes, heart disease, renal disease or liver disfunction. severe peritoneal metastasis, interstitial pneumonia or pulmonary fibrosis previous history of angina or myocardinal infarction severe drug hypersensitivity bleeding tendency
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method Progression-free survival (PFS), Overall survival(OS), Toxicity
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie paclitaxel and trastuzumab synergy in HER2-positive gastric cancer?
How does paclitaxel plus trastuzumab compare to FOLFOX in pretreated metastatic gastric cancer outcomes?
Which HER2 biomarker subtypes predict response to paclitaxel-trastuzumab combination therapy?
What are the key adverse events associated with paclitaxel-trastuzumab regimens in gastric cancer patients?
Are there alternative HER2-targeted therapies showing better efficacy than trastuzumab in gastric cancer?